1. Home
  2. ASLE vs ARMP Comparison

ASLE vs ARMP Comparison

Compare ASLE & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AerSale Corporation

ASLE

AerSale Corporation

HOLD

Current Price

$6.73

Market Cap

299.0M

ML Signal

HOLD

ARMP

Armata Pharmaceuticals Inc.

HOLD

Current Price

$11.84

Market Cap

383.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASLE
ARMP
Founded
2008
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
299.0M
383.7M
IPO Year
2018
1996

Fundamental Metrics

Financial Performance
Metric
ASLE
ARMP
Price
$6.73
$11.84
Analyst Decision
Hold
Strong Buy
Analyst Count
2
2
Target Price
$7.00
$15.00
AVG Volume (30 Days)
236.2K
38.8K
Earning Date
05-06-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
63.64
N/A
EPS
0.18
N/A
Revenue
$335,286,000.00
N/A
Revenue This Year
$23.41
N/A
Revenue Next Year
$6.80
N/A
P/E Ratio
$39.17
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.56
$1.17
52 Week High
$9.08
$13.75

Technical Indicators

Market Signals
Indicator
ASLE
ARMP
Relative Strength Index (RSI) 54.34 54.98
Support Level $5.67 $5.14
Resistance Level $7.19 $12.11
Average True Range (ATR) 0.21 1.17
MACD 0.11 0.16
Stochastic Oscillator 69.07 62.17

Price Performance

Historical Comparison
ASLE
ARMP

About ASLE AerSale Corporation

AerSale Corp offers full-service support to owners and operators of mid-life commercial aircraft. It specializes in the sale, lease, and exchange of used aircraft, engines, and components, in addition to providing various maintenance, repair, and overhaul, and engineering services for commercial aircraft and components. AerSale also offers asset management services to owners of end-of-life aircraft and engine portfolios. The company has two reportable segments: Asset Management Solutions and TechOps. Maximum revenue is generated from the Asset Management Solutions segment, which comprises activities to extract value from strategic asset acquisitions through leasing, trading, or disassembling for product sales. Geographically, the company derives maximum revenue from its domestic market.

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

Share on Social Networks: